Atlas Venture Life Science Advisors, LLC

Est. AUM

$790.0M

13F long equity, this entity only

Positions

Period

Mar 2026 (Q1)

SEC EDGAR

Mar 2026 (Q1)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	Kymera Therapeutics, Inc.	Common Stock	$381.3M	4578008	48.26%	SOLE
2	Dyne Therapeutics, Inc.	Common Stock	$165.5M	9130465	20.95%	SOLE
3	Sionna Therapeutics, Inc.	Common Stock	$120.1M	2995602	15.20%	SOLE
4	Disc Medicine, Inc.	Common Stock	$96.8M	1513875	12.25%	SOLE
5	Q32 Bio, Inc.	Common Stock	$13.4M	2092106	1.70%	SOLE
6	Korro Bio, Inc.	Common Stock	$12.9M	1137149	1.63%	SOLE

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.